The annual G-FINDER report, published on the first World NTD Day, showed that global funding for neglected disease R&D rose to $4 billion in 2018, the highest level ever recorded, and the first time that funding has grown for three consecutive years. However, funding for NTDs has been essentially flat for the past decade. In fact, it has gone backwards: funding for these diseases was almost 10% lower in 2018 than it was 2009, dropping by $34m, or 9.1%.
30 January 2019
The annual G-FINDER report provides policy-makers, donors, researchers, and industry with a comprehensive analysis of global investment into R&D of new products to prevent, diagnose, control, or cure neglected diseases in developing countries. It gives an up-to-date analysis of how R&D investments are being allocated across 36 neglected diseases, and product types, funding trends over time, and where the potential gaps lie.
Forbes [29 January 2020]
“Record funding for global health research, but neglected tropical diseases remain neglected”
Brasilia, Brazil – 5 December 2019
Studies may lead to therapeutic alternatives for people living with these neglected tropical diseases
The Brazilian Ministry of Health (the Department of Science and Technology of the Science, Technology and Strategic Inputs Secretariat – Decit/SCTIE) and CNPq (National Council for Scientific and Technological Development) will invest around R$ 1,5 million (US$ 370,000) in research that may lead to the development of a new treatment option for cutaneous leishmaniasis.
Kuala Lumpur/Geneva – 25 November 2019
DNDi is pleased to announce a contribution of USD 2.2 million (9.2 million Malaysian Ringgit) from Malaysian pharmaceutical company, Pharmaniaga, to support the registration of a new treatment combination for people living with the hepatitis C virus in Malaysia.
Geneva/Seattle – 25 November 2019
DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.
29 November 2019
- This invitation-only event marks World AIDS Day and the end of DNDi’s multi-year Unitaid grant for the development and delivery of new paediatric HIV treatment formulations.
Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.
Paris, France – le 18 octobre 2019
Bertrand Walckenaer, Directeur délégué de l’Agence française de développement, a signé, ce jour, avec Dr. Bernard Pécoul, Directeur exécutif de DNDi, un projet d’appui à la recherche et au développement de traitements contre les maladies tropicales négligées. La mise en place d’une stratégie de développement de traitements adaptés, abordables et sûrs est un enjeu majeur à l’échelle internationale : plus d’un milliard de personnes réparties dans 149 pays sont touchées par ces maladies. Le projet est une subvention d’un montant de 8 millions d’euros.
Health Policy Watch [11 October 2019]
“Bringing health innovations to market is key in the global fight against HIV/AIDS, malaria and tuberculosis”
Mitsubishi Tanabe Pharma Corporation and DNDi are pleased to announce the financial support of the Global Health Innovative Technology (GHIT) Fund for their new discovery collaboration, with a grant of EUR 130’000/JPY 15 million.
Tribune de Genève [17 September 2019]
“La cuvée de la Vigne des Nations 2018 soigne une organisation internationale” – “The 2018 vintage of ‘La Vigne des Nations’ heals an international organization”
DNDi is pleased to announce a new partnership with Takeda Pharmaceutical Company Limited whose multi-year commitment was made through Takeda employees’ voting for Global Corporate Social Responsibility (CSR) Program 2019.
Health Policy Watch [5 February 2019]
“New funding partnership to develop innovative drugs for leishmaniasis”
London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.
1 February 2019
A new research paper recently published by the AFD (Agence Française de Développement) examines how DNDi, a distinctive Product Development Partnership (PDP), can illustrate what can be presented as a “commons” in the area of public health.